Carvykti’s Revenue Continues to Increase; CARTITUDE-6 Starts Recruitment; JNJ’s Q3 2023 Earnings Call Summary
On Tuesday, October 17, JNJ held its Q3 2023 earnings call (press release / presentation) highlighting Carvykti’s (BCMA CAR-T) revenue growth and reiterated the measures implemented to raise its manufacturing capacity. Moreover, on October 13, the status of the Ph3 CARTITUDE-6 trial was updated on CT.gov to report recruitment initiation. Below, Celltelligence provides insights on the increase in Carvykti sales and evaluates the potential of its revenue to further grow in the next quarters while discussing the initiation of the CARTITUDE-6 trial.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.